Researchers are testing new combinations of drugs to treat breast cancer that’s spread to the bone, thanks to funding from Breast Cancer Now.
The charity has awarded £142,714 to Professor Penelope Ottewell at the University of Sheffield, to investigate whether a drug called radium-223, which is used to treat prostate cancer that’s spread to the bone, could be combined with other treatments to also benefit breast cancer patients.
An estimated 61,000 people are living with secondary breast cancer in the UK*. And in 70-80 per cent of women with secondary breast cancer, the disease has spread to the bone. Scientists think this is because breast cancer cells are very good at repairing their DNA when it gets damaged. The researchers will carry out tests with drugs that are already used to treat cancer, and some which are still being developed, to find out which ones are most effective at shrinking and eliminating breast cancer cells when combined with radium-223.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
University of Sheffield researching new drugs for breast cancerThe trial will use different combinations of drug to treat breast cancers that have spread to bones.
Læs mere »
New model could offer personalised breast cancer screening approach, say expertsResearchers say their study could help to potentially reduce breast cancer deaths, and cut unnecessary screenings for those at lower risk.
Læs mere »
New model could offer personalised breast cancer screening approach, say expertsResearchers say their study could help to potentially reduce breast cancer deaths, and cut unnecessary screenings for those at lower risk.
Læs mere »
Swedish study changes national guidelines for genetic testing in breast cancerBRCA1 and BRCA2 are well-known breast cancer genes associated with a significantly increased risk of hereditary breast and ovarian cancer. However, there are an additional eleven genes associated with elevated risk for these types of cancer.
Læs mere »
Personalised breast cancer screening could show death riskResearchers say breast cancer screening is vital, reducing deaths, but can sometimes detect tumours that are not harmful, which leads to unnecessary treatments
Læs mere »
Final overall study analysis continues to show benefit of sacituzumab govitecan in advanced HR+ breast cancerA novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Læs mere »